Zacks: Brokerages Expect DURECT Co. (NASDAQ:DRRX) to Announce -$0.02 Earnings Per Share

Wall Street analysts expect DURECT Co. (NASDAQ:DRRX) to report earnings of ($0.02) per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for DURECT’s earnings, with the lowest EPS estimate coming in at ($0.04) and the highest estimate coming in at $0.03. DURECT posted earnings per share of ($0.05) in the same quarter last year, which would indicate a positive year over year growth rate of 60%. The company is expected to announce its next quarterly earnings report on Thursday, March 5th.

On average, analysts expect that DURECT will report full year earnings of ($0.11) per share for the current fiscal year, with EPS estimates ranging from ($0.13) to ($0.07). For the next financial year, analysts expect that the company will post earnings of ($0.14) per share, with EPS estimates ranging from ($0.17) to ($0.10). Zacks’ EPS calculations are an average based on a survey of research firms that follow DURECT.

A number of research firms recently issued reports on DRRX. BidaskClub cut DURECT from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 7th. Craig Hallum began coverage on DURECT in a research note on Wednesday, January 22nd. They set a “buy” rating for the company. HC Wainwright reissued a “buy” rating and set a $5.50 target price on shares of DURECT in a research note on Friday, January 3rd. Cantor Fitzgerald began coverage on DURECT in a research note on Monday, November 18th. They set a “buy” rating and a $5.00 target price for the company. Finally, B. Riley began coverage on DURECT in a research note on Friday, January 31st. They set a “buy” rating and a $5.00 target price for the company. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $4.40.

In other DURECT news, major shareholder Lp Bleichroeder bought 77,500 shares of the stock in a transaction that occurred on Tuesday, February 4th. The stock was acquired at an average cost of $1.70 per share, with a total value of $131,750.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 10.20% of the stock is currently owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in DRRX. Janney Montgomery Scott LLC acquired a new position in DURECT during the 4th quarter worth approximately $46,000. Commonwealth Equity Services LLC boosted its position in DURECT by 36.9% during the 3rd quarter. Commonwealth Equity Services LLC now owns 25,955 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 7,000 shares during the last quarter. Squarepoint Ops LLC acquired a new position in DURECT during the 3rd quarter worth approximately $55,000. UBS Group AG boosted its position in DURECT by 168.7% during the 4th quarter. UBS Group AG now owns 18,979 shares of the specialty pharmaceutical company’s stock worth $72,000 after acquiring an additional 11,916 shares during the last quarter. Finally, Alambic Investment Management L.P. acquired a new position in DURECT during the 4th quarter worth approximately $81,000. 30.51% of the stock is owned by hedge funds and other institutional investors.

NASDAQ DRRX traded down $0.14 during trading hours on Friday, reaching $1.96. 939,449 shares of the company’s stock were exchanged, compared to its average volume of 2,130,948. The company’s 50-day moving average is $2.37 and its two-hundred day moving average is $1.96. DURECT has a one year low of $0.50 and a one year high of $3.95. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.72 and a current ratio of 1.81. The company has a market capitalization of $340.48 million, a price-to-earnings ratio of -14.00 and a beta of 2.12.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand.

Recommended Story: How can investors find ex-dividend dates?

Get a free copy of the Zacks research report on DURECT (DRRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.